July 9 (Reuters) - Bausch + Lomb said on Thursday its glaucoma eye drop had missed the main goal in a mid-stage trial of ...

ZOC2017217, an eye drop aimed at slowing or reversing the development of cataracts, is undergoing a pilot study ahead of a ...

Cerebral (or cortical) visual impairment (CVI) is a brain-based visual disorder that is the leading cause of pediatric visual ...

Instead of pursuing the eye drop further in glaucoma, Bausch + Lomb will focus on developing a sustained-release implant ...

Eyecare company Bausch + Lomb has had a hole blown in its pharma pipeline, after disappointing trial results forced it to ...

Very preterm infants face up to a 50% higher risk of developmental challenges affecting movement, learning, language and behavior. Today, many of those challenges are not fully recognized until later ...

High Lander and Thirdeye launch a multi-aircraft ground-based detect and avoid field program to scale BVLOS drone operations.

IAPB Chief Peter Holland met Prime Minister Tarique Rahman to discuss eye healthcare development and prevention of blindness ...

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced topline results from its Phase 2 study evaluating ...

Uncontrolled eye movements in children may signal nystagmus, a rare vision disorder where early diagnosis can protect ...

I heard Wayne had to give up driving because he is blind from glaucoma, but I saw him at the cafe reading a newspaper. I’m struggling to make sense of that: what is glaucoma?” ...